Younger women who have undergone breast conservation therapy may benefit from an MRI in addition to annual mammogram screenings.
Women who receive a false-positive mammography delay their subsequent mammography screenings.
The likelihood of a Medicare beneficiary's foregoing mammography for socioeconomic reasons is lower than before the Affordable Care Act was implemented.
An abbreviated magnetic resonance imaging (MRI) protocol can exclude malignancy in women with suspicious X-ray mammography screening.
A majority of women who receive false positives on mammography experience distress and anxiety.
Screening mammography does not impact the overall breast cancer death rate and can lead to overdiagnosis.
New research review finds limited evidence that screening prevents breast cancer deaths among women in their 40s.
Women in their 40s should talk with their doctors on whether they need regular mammograms to screen for breast cancer before age 50.
Most hospitalists feel that they should not be involved in breast cancer screening.
Mammography screening is associated with considerable costs linked to false-positive mammograms and breast cancer overdiagnosis.
Even with early diagnosis, there appears to be a disproportionate toll from breast cancer in black women.
For mammography, there has been an increase in biopsies with diagnoses of invasive carcinoma and ductal carcinoma in situ (DCIS).
Ultrasound breast screenings for women with dense breast tissue improves cancer detection.
Better breast reconstruction outcomes may be one reason behind the trend of rising mastectomy rates.
Currently, one in four women with breast cancer require a follow-up surgery for conservation.
Mammograms for those aged 69 to 75 could result in overtreatment, researchers caution.
Women overdue for screen respond better to postcard plus reminder letter from family physician.
Changes to Medicaid reimbursements can improve cancer screening rates.
MRI picks up 18.1 cancers per 1,000 missed by mammography, ultrasound.
Breast cancer survival better in women whose cancer was detected by mammography.
Despite use of newer technologies, no change has been observed in stage at diagnosis.
A study that included almost half a million mammograms suggests that tomosynthesis combined with digital mammography may become the new standard of care.
Absence of breast cancer can be established in less than 30 seconds with a negative predictive value of 99.8%.
Compared with digital mammography alone, the combination of digital mammography and tomosynthesis increases cancer detection and reduces false-positive results.
A modest 28% reduction in death from breast cancer was seen in a national mammography program that sent biennial invitations for screening.
Initial results indicate that annual magnetic resonance imaging and digital mammography can form an effective screening program for women at high risk of breast cancer.
The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma, showed that MRI detected invasive breast tumors at very early stages, when cure rates are expected to be excellent.
After adjustment for prescreening temporal trends, decrease varied from 21% to 48%.
Middle-aged breast cancer patients undergoing screening mammography are statistically less likely to be treated with chemotherapy compared to non-screened patients.
Breast tomosynthesis during diagnostic screening mammography results in less use of ultrasound, fewer biopsies, and higher positive predictive value for cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML